The local medical sector is excited with the introduction of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for treating obesity. This therapy https://bookmarkport.com/story24623976/the-new-retatrutide-australia-a-emerging-prospect-for-weight-management